The analyst recommendation below comes from a Gregory Renza @RBC Capital.My research indicates he is also known as the Acadia house broker-certainly bias is noticeable at earnings review discussions.The date of the recommendation is significant in that the recommendation was after the Blackrock interest in Acadia was well known. "TipRanks Jan. 9, 2025, 07:49 PM RBC Capital analyst Gregory Renza maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) on January 7 and set a price target of $26.00. The company’s shares closed last Wednesday at $17.60.Renza covers the Healthcare sector, focusing on stocks such as Exelixis, Jazz Pharmaceuticals, and Viridian Therapeutics. According to TipRanks, Renza has an average return of 13.3% and a 44.15% success rate on recommended stocks. The word on The Street in general suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $26.00 average price target". Kens
NEU Price at posting:
$13.66 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)